NO772339L - SUBSTITUTED TRIAZOLES. - Google Patents
SUBSTITUTED TRIAZOLES.Info
- Publication number
- NO772339L NO772339L NO772339A NO772339A NO772339L NO 772339 L NO772339 L NO 772339L NO 772339 A NO772339 A NO 772339A NO 772339 A NO772339 A NO 772339A NO 772339 L NO772339 L NO 772339L
- Authority
- NO
- Norway
- Prior art keywords
- triazole
- group
- halogen
- alkyl
- alkoxy
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- -1 3-(2-bromo-6-chloro-benzylidenehydrazino)-1,2,4-triazole Chemical compound 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
- 239000013543 active substance Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 13
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 7
- XURYEIPSEFJVEZ-UHFFFAOYSA-N n-[(2,6-dichlorophenyl)methylideneamino]-1h-1,2,4-triazol-5-amine Chemical compound ClC1=CC=CC(Cl)=C1C=NNC1=NC=NN1 XURYEIPSEFJVEZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000001631 hypertensive effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 claims description 2
- 238000006193 diazotization reaction Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 22
- DRPVUJPATHTDNQ-UHFFFAOYSA-N 1h-1,2,4-triazol-5-ylhydrazine Chemical compound NNC1=NC=NN1 DRPVUJPATHTDNQ-UHFFFAOYSA-N 0.000 claims 8
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims 4
- CRBZVDLXAIFERF-UHFFFAOYSA-N 2,4,6-trimethoxybenzaldehyde Chemical compound COC1=CC(OC)=C(C=O)C(OC)=C1 CRBZVDLXAIFERF-UHFFFAOYSA-N 0.000 claims 2
- HIKRJHFHGKZKRI-UHFFFAOYSA-N 2,4,6-trimethylbenzaldehyde Chemical compound CC1=CC(C)=C(C=O)C(C)=C1 HIKRJHFHGKZKRI-UHFFFAOYSA-N 0.000 claims 2
- JNYGYDMKLXJAOU-UHFFFAOYSA-N n-[(2,6-dimethylphenyl)methylideneamino]-1h-1,2,4-triazol-5-amine Chemical compound CC1=CC=CC(C)=C1C=NNC1=NC=NN1 JNYGYDMKLXJAOU-UHFFFAOYSA-N 0.000 claims 2
- ZIIVSQSRUPHYKS-JTQLQIEISA-N (2r)-2-hydroxy-3-iodo-2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propanamide Chemical compound IC[C@@](O)(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 ZIIVSQSRUPHYKS-JTQLQIEISA-N 0.000 claims 1
- AFUKNJHPZAVHGQ-UHFFFAOYSA-N 2,5-dimethoxy-Benzaldehyde Chemical compound COC1=CC=C(OC)C(C=O)=C1 AFUKNJHPZAVHGQ-UHFFFAOYSA-N 0.000 claims 1
- QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 claims 1
- NUGMENVSVAURGO-UHFFFAOYSA-N 2-bromo-6-chlorobenzaldehyde Chemical compound ClC1=CC=CC(Br)=C1C=O NUGMENVSVAURGO-UHFFFAOYSA-N 0.000 claims 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 claims 1
- YWSPWKXREVSQCA-UHFFFAOYSA-N 4,5-dimethoxy-2-nitrobenzaldehyde Chemical compound COC1=CC(C=O)=C([N+]([O-])=O)C=C1OC YWSPWKXREVSQCA-UHFFFAOYSA-N 0.000 claims 1
- ORCGMGUNVGVHDN-UHFFFAOYSA-N 4-fluoro-2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1C=O ORCGMGUNVGVHDN-UHFFFAOYSA-N 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004971 nitroalkyl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 239000002253 acid Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229920001592 potato starch Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229930006000 Sucrose Chemical class 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000005720 sucrose Chemical class 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Chemical class 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Chemical class OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229930195725 Mannitol Chemical class 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000000594 mannitol Chemical class 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Chemical class 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- JGGFDEJXWLAQKR-UHFFFAOYSA-N 1,2-diaminoguanidine Chemical compound NNC(N)=NN JGGFDEJXWLAQKR-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- KHCYGOIWSWLPNL-UHFFFAOYSA-N 3-n-[(2,6-dichlorophenyl)methylideneamino]-1,2,4-triazole-3,4-diamine Chemical compound NN1C=NN=C1NN=CC1=C(Cl)C=CC=C1Cl KHCYGOIWSWLPNL-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- BWSWPOJRYCYBRQ-UHFFFAOYSA-N 4h-1,2,4-triazol-4-ium;chloride Chemical compound Cl.C=1N=CNN=1 BWSWPOJRYCYBRQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000008120 corn starch Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Substituerte triazoler.Substituted triazoles.
Oppfinnelsen vedrører nye triazoler, fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende disse og fremgangsmåte for behandling av hypertensive tilstander. The invention relates to new triazoles, methods for their preparation, pharmaceutical preparations containing them and methods for treating hypertensive conditions.
Hensikten med oppfinnelsen er å tilveiebringe forbindelser som har en terapeutisk effekt ved behandling av hypertensive tilstander. The purpose of the invention is to provide compounds which have a therapeutic effect in the treatment of hypertensive conditions.
Hypertensive midler har vært kjent i lengere tid. Det er også kjent at disse midler utøver deres virkning gjennom forskjellige virkningsmekanismer. Bivirkninger som har kliniske resultater av stor viktighet møtes ofte blant disse forbindelser. Et velkjent eksempel er en økning i blodtrykket for en kortere eller lengere tid etter administrering og før starting av det ønskede fall i blodtrykket. Et ytterligere eksempel er den seda-tive effekt av disse midler som kan gjøre disse midler uegnet for bruk av personer som utøyer en eller annen form for arbeide som krever sterk oppmerksomhet, ffeks. bilkjøring. Hypertensive agents have been known for a long time. It is also known that these agents exert their effect through different mechanisms of action. Side effects that have clinical results of great importance are often encountered among these compounds. A well-known example is an increase in blood pressure for a shorter or longer time after administration and before the start of the desired drop in blood pressure. A further example is the sedative effect of these agents, which can make these agents unsuitable for use by people who carry out some form of work that requires strong attention, e.g. car driving.
Substituerte triazoler med hypotensiv effekt er kjent fra de svenske patentsøknader 73 08 365-1 og 7^ 15 579-7• Substituted triazoles with hypotensive effect are known from the Swedish patent applications 73 08 365-1 and 7^ 15 579-7•
Det er nå funnet at visse substituerte forbindelser beslektet til 3_benzyliden-hydrazino-1,2,4-triazoler har evnen til å senke det arterielle blodtrykk i ikke-anesteserte dyr med eksperimentelt indusert hypertensjon i orale doser som ikke bevirker sedatering eller andre bivirkninger. It has now been found that certain substituted compounds related to 3-benzylidene-hydrazino-1,2,4-triazoles have the ability to lower the arterial blood pressure in non-anesthetized animals with experimentally induced hypertension at oral doses that do not cause sedation or other side effects.
Slike substituerte triazoler har den generelle formel I hvori Rx 1 og R 2 kan være like eller.forskjellige og hver bety en del av gruppen bestående av hydrogen, nitro, alkyl, alkoksy, alkoksyalkyl og halogen; R-^ er valgt blant gruppen bestående av hydrogen, alkyl, halogen,- alkoksy og nitro, og n er et helt tall Such substituted triazoles have the general formula I in which Rx 1 and R 2 may be the same or different and each represents part of the group consisting of hydrogen, nitro, alkyl, alkoxy, alkoxyalkyl and halogen; R-^ is selected from the group consisting of hydrogen, alkyl, halogen, - alkoxy and nitro, and n is an integer
1 eller 2 samt farmasøytisk tålbare salter herav.1 or 2 as well as pharmaceutically acceptable salts thereof.
Alkyl R<1>og R er fortrinnsvis lavere alkyl med opptil 7 karbonatomer, fortrinnsvis opptil 4 karbonatomer, og er f.eks. metyl, etyl, n-propyl, isopropyl, n-butyl, sek.-butyl, isobutyl og tert.-butyl. 12 . Alkyl R<1> and R are preferably lower alkyl with up to 7 carbon atoms, preferably up to 4 carbon atoms, and are e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl. 12 .
Alkoksy R og R er fortrinnsvis lavere alkoksy med opptil 7 karbonatomer, spesielt opptil 4 karbonatomer og er f.eks. metoksy, etoksy,n-propoksy, isopropoksy, n-butoksy, sek.-butoksy, isobutoksy, tert.-butoksy. Alkoxy R and R are preferably lower alkoxy with up to 7 carbon atoms, especially up to 4 carbon atoms and are e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy.
Alkoksyalkyl R<1>og R<2>er fortrinnsvis lavere alkoksyalkyl med opptil 7 karbonatomer i hver alkyldel, spesielt opptil 4 karbonatomer..! hver alkyldel og er f..eks. metoksymetyl, metoksyetyl, metoksy n-propyl, etoksymetyl, etoksyetyl, etoksy-isopropyl, tert.-butoksymetyl og metoksy-tert.-butyl. Alkoxyalkyl R<1> and R<2> are preferably lower alkoxyalkyl with up to 7 carbon atoms in each alkyl part, especially up to 4 carbon atoms..! each alkyl part and is e.g. methoxymethyl, methoxyethyl, methoxy n-propyl, ethoxymethyl, ethoxyethyl, ethoxy-isopropyl, tert-butoxymethyl and methoxy-tert-butyl.
12' 12'
Halogen R og R er brom, jod, klor eller fluor. Halogen R and R are bromine, iodine, chlorine or fluorine.
Alkyl R^ har samme betydning som alkyl R-'- og R<2>ovenfor. Halogen EJ x har samme betydni. ng som halogen Rx i og R<2>ovenfor. Alkyl R^ has the same meaning as alkyl R-'- and R<2> above. Halogen EJ x has the same meaning. ng as halogen Rx in and R<2> above.
Alkoksy R^ (alkyl-O-) er fortrinnsvis en alkoksy-gruppe som har opptil 7 karbonatomer, mer spesielt opptil 4 karbonatomer og er f.eks. metoksy, etoksyn-propoksy, isopropoksy, n-butoksy og tert.-butoksy. Alkoxy R 1 (alkyl-O-) is preferably an alkoxy group having up to 7 carbon atoms, more particularly up to 4 carbon atoms and is e.g. methoxy, ethoxy-propoxy, isopropoxy, n-butoxy and tert-butoxy.
NitroR^ er gruppen -N02.NitroR^ is the group -N02.
Poretrukkede forbindelser ifølge oppfinnelsen er:Porous compounds according to the invention are:
1) 3_(2,6-dimetylbenzylidenhydrazino)-l,2,4-triazoler,1) 3_(2,6-dimethylbenzylidenehydrazino)-1,2,4-triazoles,
2) 3_(2,4,6-trimetoksybenzylidenhydrazino)-1,2,4-triazoler,2) 3_(2,4,6-trimethoxybenzylidenehydrazino)-1,2,4-triazoles,
3) 3_(2-brom-6-klorbenzylidenhydrazino)-1,2,4-triazoler,3) 3_(2-bromo-6-chlorobenzylidenehydrazino)-1,2,4-triazoles,
4) 3-(2,6-diklorbenzylidenhydrazino)-1,2,4-triazoler,4) 3-(2,6-dichlorobenzylidenehydrazino)-1,2,4-triazoles,
B) 3-(3j4-diklorbenzylidenhydrazino)-1,2,4-triazoler,B) 3-(3j4-dichlorobenzylidenehydrazino)-1,2,4-triazoles,
6) 3-(2,5-dimetoksybenzylidenhydrazino)-1,2,4-triazoler,6) 3-(2,5-dimethoxybenzylidenehydrazino)-1,2,4-triazoles,
7) 3~(4-f1uor-2-nitrobenzylidenhydrazino)-1,2,4-triazoler, 7) 3~(4-fluoro-2-nitrobenzylidenehydrazino)-1,2,4-triazoles,
8) 3~(4,5-dimetoksy-2-nitrobenzylidenhydrazino)-1,2,4-triazoler, 9) 3-(2,4,6-trimetylbenzylidenhydrazino)-l,2,4-triazoler. 8) 3-(4,5-dimethoxy-2-nitrobenzylidenehydrazino)-1,2,4-triazoles, 9) 3-(2,4,6-trimethylbenzylidenehydrazino)-1,2,4-triazoles.
Forbindelsene kan fremstilles i .henhold til analogi-fremgangsmåter: The compounds can be prepared according to analogical methods:
Forbindelse med formel I kan fremstilles entenCompound of formula I can be prepared either
a) ved omsetning av en forbindelse med formel IIIa) when converting a compound of formula III
12 3 hvori R , R , R-' og n har overnevnte betydning med en forbindelse med formel IV 12 3 in which R , R , R-' and n have the above meaning with a compound of formula IV
hvori R 4 og Rb har overnevnte betydning for dannelse av en forbindelse med formel I, eller in which R 4 and Rb have the above meaning for the formation of a compound of formula I, or
- b) ved omsetning av en forbindelse med formel V- b) when converting a compound of formula V
1 ? 3 hvori R , R , R og n har overnevnte betydning med en forbindelse med formel VI 1 ? 3 in which R , R , R and n have the above meaning with a compound of formula VI
for dannelsen av en forbindelse med formel I, og for the formation of a compound of formula I, and
c) ved diazotering av en forbindelse med formel VII c) by diazotization of a compound of formula VII
hvori R 1 , R^p ,, R- x" og n har overnevnte betydning for dannelse av en forbindelse med formel I. in which R 1 , R^p ,, R- x" and n have the above meaning for the formation of a compound of formula I.
Avhengig av fremgangsmåtebetingelser og utgangs-materialer fremkommer sluttproduktet enten som fri base eller i form av syreaddisjonssalt, hvorav begge omfattes av oppfinnelsen. Således kan basiske, nøytrale og blandede salter oppnås såvel som hemiamino, sesqui- eller polyhydrater. Syreaddisjonssaltene av de nye forbindelser kan på i og for seg kjent måte overføres i den fri base, idet det benyttes basiske midler som alkali eller ved -ioneutveksling. På den annen side kan de fri baser som dannes danne spalter med organiske eller uorganiske syrer. Ved fremstilling av syreaddisjonssalter benyttes fortrinnsvis slike syrer som danner egnede terapeutisk tålbare salter. Slike syrer, omfatter hydrohalogensyrer, sulfonsyreå fosforsyre, salpetersyre og perklorsyrer; alifatiske, alicykliske, aromatiske, hetero-cykliske karboksy eller sulfonsyrer som maursyre, eddiksyre, pro-pionsyre, ravsyre, glykolsyre, melkesyreeplesyre, vinsyre, sitronsyre, askorbinsyre, maleinsyre, hydroksymaleinsyre, pyro-druesyre, fenyleddiksyre, benzosyre, p-aminobenzosyre, antranil-syre, p-hydroksybenzoinsyre, salicylsyre eller p-aminosalicyl-syre, embonsyre, metansulfonsyre, etansulfonsyre, hydroksyetan-sulfonsyre, etylensulfonsyre, halogenbenzensulfonsyre, toluen-sulfonsyre, naftyl-sulfonsyre eller sulfanilsyrer, metionin, tryptofan, lysin eller arginin. Depending on process conditions and starting materials, the final product appears either as a free base or in the form of an acid addition salt, both of which are covered by the invention. Thus, basic, neutral and mixed salts can be obtained as well as hemiamino, sesqui- or polyhydrates. The acid addition salts of the new compounds can be transferred in a manner known per se into the free base, using basic agents such as alkali or by ion exchange. On the other hand, the free bases that are formed can form cleavages with organic or inorganic acids. In the preparation of acid addition salts, such acids are preferably used which form suitable therapeutically tolerable salts. Such acids include hydrohalic acids, sulphonic acid and phosphoric acid, nitric acid and perchloric acids; aliphatic, alicyclic, aromatic, heterocyclic carboxy or sulfonic acids such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, anthranilic acid -acid, p-hydroxybenzoic acid, salicylic acid or p-aminosalicylic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, halobenzenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid or sulfanilic acids, methionine, tryptophan, lysine or arginine.
Disse eller andre salter av de nye forbindelser,These or other salts of the new compounds,
som f.eks. pikrater kan tjene som rensemidler for de dannede fri baser. Salter av basene kan dannes, adskilles fra oppløsningen og deretter kan den fri base frigjøres fra en ny saltoppløsning i en renere tilstand. På grunn av det nære forhold mellom de nye forbindelser i fri basisk form og deres salter skal det forstås at de tilsvarende salter omfattes av oppfinnelsen. like for example. picrates can serve as scavengers for the formed free bases. Salts of the bases can be formed, separated from the solution and then the free base can be released from a new salt solution in a purer state. Due to the close relationship between the new compounds in free basic form and their salts, it should be understood that the corresponding salts are covered by the invention.
Utgangsmaterialene er kjent eller kan, hvis de er nye, oppnås ifølge i og for seg kjente fremgangsmåter. The starting materials are known or, if they are new, can be obtained according to methods known per se.
I klinisk bruk blir forbindelsene fremstillet ifølge oppfinnelsen administrert oralt, rektalt eller ved injeksjon i form av et farmasøytisk preparat som inneholder en aktiv forbindelse.^, enten som en fri base eller som.et farmasøytisk tålbart, ikke-toksisk syreaddisjonssalt som hydroklorid, laktat, acetat, sulfamat, i kombinasjon med farmasøytisk vanlige bærere. In clinical use, the compounds produced according to the invention are administered orally, rectally or by injection in the form of a pharmaceutical preparation containing an active compound, either as a free base or as a pharmaceutically acceptable, non-toxic acid addition salt such as hydrochloride, lactate, acetate, sulfamate, in combination with pharmaceutically customary carriers.
Bærerne kan være i form av et fast stoff, halvfast eller flytende fortynningsmiddel eller en kapsel. Disse farmasøytiske preparater omfattes også av oppfinnelsen. Vanligvis er mengden av den aktive forbindelse mellom 0,1 og 99 vekt$ for preparatet, mellom 0,5 til 20 vekt% i injeksjonspreparater og mellom 2 og 50 vekt% i preparater for oral administrering. The carriers may be in the form of a solid, semi-solid or liquid diluent or a capsule. These pharmaceutical preparations are also covered by the invention. Generally, the amount of the active compound is between 0.1 and 99% by weight of the preparation, between 0.5 to 20% by weight in injectable preparations and between 2 and 50% by weight in preparations for oral administration.
Ved fremstillingen av de farmasøytiske preparater som inneholder en forbindelse fremstillet ifølge oppfinnelsen i form av dosisenheter for oral administrering, kan den aktuelle forbindelse blandes med en fast pulverformet bærer som laktose, sakkarose, sorbitol, mannitol, stivelse, amylopektin, cellulosederivater eller gelatin, såvel som med et glidemiddel som magnesiumstearat, kalsiumstearat og polyetylenglykolvoks. Blandingen presses deretter til tabletter. Hvis det er ønsket belagte tabletter kan overnevnte fremstilte kjerne belegges med en konsentrert sukkeroppløsning, som kan inneholde gummi arabicum, gelatin, talkum, titandioksyd eller med en lakk oppløst i et flyktig organisk oppløsningsmiddel eller blanding av oppløsningsmidler. Til dette belegg kan det settes forskjellige farver for å ad-skille mellom tabletter med forskjellige aktive forbindelser eller med forskjellige mengder av den aktive forbindelse som er tilstede. In the preparation of the pharmaceutical preparations containing a compound produced according to the invention in the form of dosage units for oral administration, the relevant compound can be mixed with a solid powdered carrier such as lactose, sucrose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives or gelatin, as well as with a lubricant such as magnesium stearate, calcium stearate and polyethylene glycol wax. The mixture is then pressed into tablets. If coated tablets are desired, the above-mentioned prepared core can be coated with a concentrated sugar solution, which may contain gum arabic, gelatin, talc, titanium dioxide or with a varnish dissolved in a volatile organic solvent or mixture of solvents. Different colors can be added to this coating to distinguish between tablets with different active compounds or with different amounts of the active compound present.
Myke gelatinkapsler kan fremstilles hvilke kapsler inneholder en blanding.av den aktive forbindelse eller forbindelser fremstillet ifølge oppfinnelsen av vegetabilsk olje. Hårde gelatinkapsler kan inneholde granuler av den aktive forbindelse i kombinasjon med en fast pulverformet bærer som laktose, sakkarose, sorbitol, mannitol, potetstivelse, kornstivelse, amylopektin, cellulosederivater eller gelatin. Soft gelatin capsules can be prepared which capsules contain a mixture of the active compound or compounds produced according to the invention from vegetable oil. Hard gelatin capsules may contain granules of the active compound in combination with a solid powdered carrier such as lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
Dosisenheter forrrektal administrering kan fremstilles i form av suppositorier som inneholder det.aktive stoff i en blanding med en nøytral fettbase, eller de kan fremstilles i form av gelatin-rektalkapsler som inneholder det aktive stoff i en blanding med vegetabilsk olje eller parafinolje. Dosage units for rectal administration can be prepared in the form of suppositories containing the active substance in a mixture with a neutral fat base, or they can be prepared in the form of gelatin rectal capsules containing the active substance in a mixture with vegetable oil or paraffin oil.
Flytende preparater for oral administrering kan fremstilles i form av siruper eller.suspensjoner, f.eks. oppløs-ninger inneholdende fra 0,2 til 20 vekt$ av det aktive stoff og resten bestående av sukker og en blanding av etanol, vann, glycerol og propylenglykol. Hvis ønsket kan slike flytende preparater inneholde farvemidler, smaksmidler, sakkarin og karboksymetylcellulose som fortykningsmidde1. Liquid preparations for oral administration can be prepared in the form of syrups or suspensions, e.g. solutions containing from 0.2 to 20% by weight of the active substance and the rest consisting of sugar and a mixture of ethanol, water, glycerol and propylene glycol. If desired, such liquid preparations can contain coloring agents, flavourings, saccharin and carboxymethyl cellulose as a thickening agent1.
Oppløsninger for parenteral administrering ved injeksjon kan fremstilles som en vandig oppløsning avet vann-oppløselig farmasøytisk tålbart salt av den aktive forbindelse, fortrinnsvis i en konsentrasjon fra 0,5 til 10 vekt$. Disse opp-løsninger kan også inneholde stabiliseringsmidler og/eller puffer-stoffer og kan fremstilles i forskjellige dosisenhetsampuller. Solutions for parenteral administration by injection may be prepared as an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active compound, preferably in a concentration of from 0.5 to 10% by weight. These solutions can also contain stabilizers and/or buffer substances and can be produced in different dosage unit ampoules.
Farmasøytiske tabletter for oral bruk fremstillesPharmaceutical tablets for oral use are manufactured
på følgende måte: De faste stoffer males eller siktes til en ønsket partikkelstørrelse og bindemidlet homogeniseres og for-deles i et egnet oppløsningsmiddel. De terapeutisk aktive forbindelser og hjelpemidler blandes med bindemiddeloppløsningen. Den resulterende blanding fuktes for å danne en jevn suspensjon som., har konsistens av fuktig sne. Fuktningen bevirker at par-tiklene aggregerer lett og den resulterende masse presses gjennom en rustfri stålsikt som har en maskestørrelse på omtrent 1 mm. Lagene av blandingen tørkes i omhyggelig kontrollerte tørkeskap in the following way: The solids are ground or sieved to a desired particle size and the binder is homogenised and distributed in a suitable solvent. The therapeutically active compounds and excipients are mixed with the binder solution. The resulting mixture is moistened to form a smooth suspension having the consistency of wet snow. The moistening causes the particles to aggregate easily and the resulting mass is pressed through a stainless steel sieve having a mesh size of approximately 1 mm. The layers of the mixture are dried in carefully controlled drying cabinets
i omtrent 10 timer for å oppnå den ønskede'partikkelstørrelse og konsistens. Granulatet av den tørkede blanding siktes for å fjerne pulver. Til denne blanding settes sprengmidler, anti-friksjonsmidler og antiadhesiver. Endelig presses blandingen til tabletter, idet det brukes maskiner med egnet stempel og synke ifior å oppnå en ønsket tablettstørrelse. Det anvendte trykk påvirker størrelsen av tabletten, styrken og evnen til å oppløse i vann. Det anvendte kompresjonstrykk bør være i området 0,5 til 5 tonn. Tabletter fremstilles med en hastighet på 20.000 til 200.000 pr. time. Tablettene, spesielt de som er ru eller bitre, kan belegges med et lag av sukker eller andre for about 10 hours to achieve the desired particle size and consistency. The granulate of the dried mixture is sieved to remove powder. Blasting agents, anti-friction agents and anti-adhesives are added to this mixture. Finally, the mixture is pressed into tablets, using machines with suitable pistons and sinkers to achieve a desired tablet size. The pressure applied affects the size of the tablet, its strength and its ability to dissolve in water. The applied compression pressure should be in the range of 0.5 to 5 tonnes. Tablets are produced at a rate of 20,000 to 200,000 per hour. The tablets, especially those that are rough or bitter, may be coated with a layer of sugar or others
stoffer. De pakkes deretter av maskiner som har elektriske telle-innretninger. De forskjellige typer forpakninger består av glass eller plastikkbeholdere, bokser, rør ogsspesielle doser tilpasset pakningen. substances. They are then packed by machines that have electrical counting devices. The different types of packaging consist of glass or plastic containers, cans, tubes and special doses adapted to the packaging.
Den typiske daglige dose av det aktive stoff varierer ifølge det individuelle behov og administreringsmåte. Vanligvis er orale doser fra 100 til 1000 mg.pr. dag aktivt stoff og intravenøse doser fra 5 til 40 mg pr. dag. The typical daily dose of the active substance varies according to individual needs and method of administration. Usually oral doses are from 100 to 1000 mg.pr. day active substance and intravenous doses from 5 to 40 mg per day.
Oppfinnelsen skal forklares nærmere ved hjelp av noen eksempler. The invention will be explained in more detail with the help of some examples.
Eksempel 1.Example 1.
9,6 g 3-hydrazino-l,2,4-triazol dihydroklorid opp-løses i 10 ml H2O og 95 ml 96$ etanol under oppvarmning. Til oppløsningen ble det satt 9, 8 g 2,6-diklorbenzaldehyd etterhvert, hvorpå blandingen tilbakeløpskokes natten over. Reaksjonsbland-ingen ble deretter avkjølt og fortynnet med like volum isopropyleter og filtrert. De dannede krystaller ble oppvarmet i etanol, avkjølt, filtrert og vasket med isopropyleter. Endelig ble om-krystallisering utført fra vann. På denne måte fremkom 3-(2,6-diklorbenzylidenhydrazino)-1,2,4-triazol med smeltepunkt 194°C. Eksempel 2. (Fremgangsmåte b). 9.6 g of 3-hydrazino-1,2,4-triazole dihydrochloride are dissolved in 10 ml of H2O and 95 ml of 96$ ethanol while heating. 9.8 g of 2,6-dichlorobenzaldehyde was gradually added to the solution, after which the mixture was refluxed overnight. The reaction mixture was then cooled and diluted with an equal volume of isopropyl ether and filtered. The formed crystals were heated in ethanol, cooled, filtered and washed with isopropyl ether. Finally, recrystallization was carried out from water. In this way, 3-(2,6-dichlorobenzylidenehydrazino)-1,2,4-triazole with a melting point of 194°C was obtained. Example 2. (Procedure b).
17>5g diklorbenzaldehyd og 12,6 g N,N'-diaminogua-nidin ble oppløst i 100 ml 99$ etanol og tilbakeløpskokt natten over. Deretter ble oppløsningsmidlet fordampet og residuet ble oppløst i 100 ml 98% maursyre og tilbakeløpskokt i 30 minutter. Oppløsningen ble avkjølt til ca. 50°C, hvorpå det ble tilsatt 17>5 g of dichlorobenzaldehyde and 12.6 g of N,N'-diaminoguanidine were dissolved in 100 ml of 99% ethanol and refluxed overnight. Then the solvent was evaporated and the residue was dissolved in 100 ml of 98% formic acid and refluxed for 30 minutes. The solution was cooled to approx. 50°C, whereupon it was added
100 ml 6 N HC1 og blandingen ble tilbakeløpskokt ytterligere 30 minutter. Under avkjøling utkrystalliserte 3-(2,6-diklor-benzylidenhydrazino)-1,2,4-triazol . hydroklorid. Krystallene ble frafiltrert og vasket med etanol og tørket. Utbytte 65%. Smeltepunkt 194°C. 100 ml of 6N HCl and the mixture was refluxed for a further 30 minutes. During cooling, 3-(2,6-dichloro-benzylidenehydrazino)-1,2,4-triazole crystallized out. hydrochloride. The crystals were filtered off and washed with ethanol and dried. Yield 65%. Melting point 194°C.
Eksempel 3. (Fremgangsmåte c).Example 3. (Procedure c).
10 g 4-amino-3_(2,6-diklorbenzylidenhydrazino)-l,2,4-triazol ble oppløst i 125 ml metanol og 1 ml konsentrert HC1. Ved en temperatur på -5°C til 0°C ble det dråpevis tilsatt en oppløs-ning av 2,2 g NaN02i 25 ml H2O. Deretter ble hele blandingen omrørt natten over ved værelsestemperatur, oppløsningsmidlet ble fordampet og residuet gjort alkalisk med en oppløsning av NaHCO^. Etter filtrering ble det dannede faste stoff oppløst i etanol og surgjort med konsentrert HC1, hvorpå det fremkom hy.drokloridet ved tilsetning av isopropyleter. Endelig ble 3-(2,6-diklorben-zylidenhydrazino)-1,2,4-triazol . hydroklorid omkrystallisert fra vann. Utbytte 59%. Smeltepunkt 194°C. 10 g of 4-amino-3-(2,6-dichlorobenzylidenehydrazino)-1,2,4-triazole was dissolved in 125 ml of methanol and 1 ml of concentrated HCl. At a temperature of -5°C to 0°C, a solution of 2.2 g NaN02 in 25 ml H2O was added dropwise. Then the whole mixture was stirred overnight at room temperature, the solvent was evaporated and the residue made alkaline with a solution of NaHCO 3 . After filtration, the solid formed was dissolved in ethanol and acidified with concentrated HCl, after which the hydrochloride was formed by the addition of isopropyl ether. Finally, 3-(2,6-dichloroben-zylidenehydrazino)-1,2,4-triazole . hydrochloride recrystallized from water. Yield 59%. Melting point 194°C.
Overensstemmende med eksempel 1 ovenfor ble det fremstillet følgende forbindelser. Alle de angitte smeltepunkter refererer seg til basen. In accordance with Example 1 above, the following compounds were prepared. All melting points given refer to the base.
Eksempel 22 . Example 22.
En sirup inneholdende2% (vekt pr. volum) av aktivt stoff ble fremstillet av følgende forbindelser: A syrup containing 2% (weight per volume) of active substance was prepared from the following compounds:
Destillert vann (tilstrekkelig til å oppnå et sluttvolum på 100 ml). Distilled water (enough to achieve a final volume of 100 ml).
Sukker, sakkarin og syreaddisjonssalter ble oppløstSugar, saccharin and acid addition salts were dissolved
i 60 g varmt vann. Etter avkj øling .ble det tilsatt glycerol og en oppløsning av smaksxniddel oppløst i etanol. Til blandingen ble det satt vann for å oppnå et sluttvolum på 100 ml. in 60 g of warm water. After cooling, glycerol and a solution of flavoring agent dissolved in ethanol were added. Water was added to the mixture to obtain a final volume of 100 ml.
Overnevnte aktive stoff kan erstattes med andre farmasøytisk tålbare syreaddisjonssalter. The above-mentioned active substance can be replaced with other pharmaceutically acceptable acid addition salts.
Eksempel 23.Example 23.
■ 3-(2,6-dimetoksybenzylidenhydrazino)-1,2,4-triazol . HG1 (250 g) ble blandet med laktose (175,8 g), potetstivelse ■ 3-(2,6-dimethoxybenzylidenehydrazino)-1,2,4-triazole . HG1 (250 g) was mixed with lactose (175.8 g), potato starch
(169 7 g) og kolloidal siliciumsyre (32 g). Blandingen ble fuktet med 10% oppløsning av gelatin og ble malt gjennom en 12 maskesikt. Etter tørkning ble det tilsatt potetstivelse (l60 g), talkum (169 7 g) and colloidal silicic acid (32 g). The mixture was moistened with a 10% solution of gelatin and ground through a 12 mesh sieve. After drying, potato starch (160 g), talc was added
(50 g) og magnesiumstearat (5 g) og blandingen ble presset til (50 g) and magnesium stearate (5 g) and the mixture was pressed
tabletter (10.000), hver tablett inneholdt 25 mg aktivt stoff.tablets (10,000), each tablet contained 25 mg of active substance.
Det kan fremstilles tabletter som inneholder en hvilken som helst ønsket mengde aktivt stoff. Tablets containing any desired amount of active substance can be prepared.
Eksempel 24.Example 24.
Granuler ble fremstillet av 3_(2,6-dimetylbenzylidenhydrazino)-1,2,4 triazolhydroklorid (250 g), laktose (17539 g) og en alkoholisk oppløsning av polyvinylpyrrolidon (25 g)• Etter tørkning ble granulene blandet med talkum (.25 g) , potetstivelse (40 g) og magnesiumstearat (2,50 g) og presset til 10.000 tabletter. Disse tabletter belegges først med en 10%-ig alkoholisk oppløsning av shellakk og derpå med en vandig oppløsning inneholdende sakkarose (45%), gummi arabikum ( 5%), gelatin (4%) og farvestoff ( 0, 2%). Talkum og pulverisert sukker.ble benyttet for pudring etter de første fem belegg. Belegget ble'deretter dekket med en 66%- ig sukkersirup og polert med en oppløsningav 10% karnaubavoks i karbontetraklorid. Granules were prepared from 3_(2,6-dimethylbenzylidenehydrazino)-1,2,4 triazole hydrochloride (250 g), lactose (17539 g) and an alcoholic solution of polyvinylpyrrolidone (25 g)• After drying, the granules were mixed with talc (.25 g), potato starch (40 g) and magnesium stearate (2.50 g) and pressed into 10,000 tablets. These tablets are first coated with a 10% alcoholic solution of shellac and then with an aqueous solution containing sucrose (45%), gum arabic (5%), gelatin (4%) and dye (0.2%). Talc and powdered sugar were used for dusting after the first five coatings. The coating was then covered with a 66% sugar syrup and polished with a solution of 10% carnauba wax in carbon tetrachloride.
Eksempel 25.Example 25.
3- (2-brom-6--klorbenzylidenhydrazino)■ 1,2, 4-triazol hydroklorid (1 g), natriumklorid (0,8 g) og askorbinsyre (0,1 g) ble oppløst i en tilstrekkelig mengde destillert vann for å danne 100 ml oppløsning. Denne oppløsning som inneholder 10 mg aktivt stoff pr. ml, ble benytfeet i fylling av ampuller, som ble sterili-sert ved oppvarmning ved 120°C i 20 minutter. 3-(2-bromo-6--chlorobenzylidenehydrazino)■ 1,2,4-triazole hydrochloride (1 g), sodium chloride (0.8 g) and ascorbic acid (0.1 g) were dissolved in a sufficient amount of distilled water for to form 100 ml of solution. This solution, which contains 10 mg of active substance per ml, was used in filling ampoules, which were sterilized by heating at 120°C for 20 minutes.
Biologiske effekter.Biological effects.
Den antihypertensive effekt av forbindelsen ifølge eksempel 1 ble undersøkt i bevisste, ikke hemmede rotter med spontan hypertensjon. Dyrene ble preparert for å opptegne arteri elle blodtrykk ved foregående implantasjon av et kateter inn i aorta via-karotidarterien. Forbindelsen ifølge eksempel 1 ble gitt til seks rotter i tre suksessive orale doser, 5320 og 100/Umol pr. kg legemsvekt ved 2 timers intervaller. Seks rotter danner en kontrollgruppe og ble gitt bare bæreren (5% "Methocel" i vann; 5 ml/kg legemsvekt) ved samme tidsintervaller. The antihypertensive effect of the compound of Example 1 was investigated in conscious, unrestrained rats with spontaneous hypertension. The animals were prepared to record arterial blood pressure prior to implantation of a catheter into the aorta via the carotid artery. The compound according to example 1 was given to six rats in three successive oral doses, 5320 and 100/Umol per kg body weight at 2-hour intervals. Six rats form a control group and were given only the vehicle (5% "Methocel" in water; 5 ml/kg body weight) at the same time intervals.
Verdier for blodtrykk før administrering og 2 timer etter hver dose angis i nedenstående tabell 2. Values for blood pressure before administration and 2 hours after each dose are given in table 2 below.
Det er klart at forbindelsen ifølge eks. 1 senker blodtrykket i en dosisavhengig måte og at varigheten av antihyper-tensiv-virkningen strekker seg over 2 timer. I dosene som ble undersøkt var forbindelsene ifølge eks. 1 fri for synlige bivirkninger med hensyn til oppførsel og bevegelsesaktivitet etc. It is clear that the connection according to e.g. 1 lowers blood pressure in a dose-dependent manner and that the duration of the antihypertensive effect extends over 2 hours. In the doses that were examined, the compounds according to e.g. 1 free of visible side effects with regard to behavior and movement activity etc.
Noen data oppnådd for andre forbindelser ifølge oppfinnelsen .angis nedenfor i tabell 3. Forbindelsene ble undersøkt som ovenfor. Some data obtained for other compounds of the invention are given below in Table 3. The compounds were tested as above.
Claims (58)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7607653A SE7607653L (en) | 1976-07-05 | 1976-07-05 | SUBSTITUTED TRIAZOLES |
Publications (1)
Publication Number | Publication Date |
---|---|
NO772339L true NO772339L (en) | 1978-01-06 |
Family
ID=20328383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO772339A NO772339L (en) | 1976-07-05 | 1977-07-01 | SUBSTITUTED TRIAZOLES. |
Country Status (16)
Country | Link |
---|---|
JP (1) | JPS535168A (en) |
AT (1) | AT351529B (en) |
AU (1) | AU2650677A (en) |
BE (1) | BE856356A (en) |
DD (1) | DD130478A5 (en) |
DE (1) | DE2727333A1 (en) |
DK (1) | DK295377A (en) |
FI (1) | FI772013A (en) |
FR (1) | FR2357549A1 (en) |
HU (1) | HU172956B (en) |
LU (1) | LU77684A1 (en) |
NL (1) | NL7707445A (en) |
NO (1) | NO772339L (en) |
SE (1) | SE7607653L (en) |
SU (1) | SU664562A3 (en) |
ZA (1) | ZA773470B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4338453A (en) | 1980-09-17 | 1982-07-06 | The Upjohn Company | Aminoalkyl-1,2,4-triazoles |
GB201300435D0 (en) | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
-
1976
- 1976-07-05 SE SE7607653A patent/SE7607653L/en unknown
-
1977
- 1977-06-04 HU HU77HE00000739A patent/HU172956B/en unknown
- 1977-06-08 ZA ZA00773470A patent/ZA773470B/en unknown
- 1977-06-16 DE DE19772727333 patent/DE2727333A1/en active Pending
- 1977-06-24 AT AT446877A patent/AT351529B/en not_active IP Right Cessation
- 1977-06-27 AU AU26506/77A patent/AU2650677A/en active Pending
- 1977-06-28 FI FI772013A patent/FI772013A/fi not_active Application Discontinuation
- 1977-07-01 BE BE178983A patent/BE856356A/en unknown
- 1977-07-01 DK DK295377A patent/DK295377A/en unknown
- 1977-07-01 NO NO772339A patent/NO772339L/en unknown
- 1977-07-01 DD DD7700199841A patent/DD130478A5/en unknown
- 1977-07-04 SU SU772499560A patent/SU664562A3/en active
- 1977-07-04 LU LU77684A patent/LU77684A1/xx unknown
- 1977-07-04 FR FR7720495A patent/FR2357549A1/en active Granted
- 1977-07-05 NL NL7707445A patent/NL7707445A/en unknown
- 1977-07-05 JP JP7958577A patent/JPS535168A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA773470B (en) | 1978-04-26 |
NL7707445A (en) | 1978-01-09 |
FR2357549A1 (en) | 1978-02-03 |
AT351529B (en) | 1979-07-25 |
HU172956B (en) | 1979-01-28 |
DK295377A (en) | 1978-01-06 |
DD130478A5 (en) | 1978-04-05 |
FI772013A (en) | 1978-01-06 |
FR2357549B1 (en) | 1979-07-20 |
ATA446877A (en) | 1979-01-15 |
SE7607653L (en) | 1978-01-06 |
BE856356A (en) | 1978-01-02 |
DE2727333A1 (en) | 1978-01-12 |
JPS535168A (en) | 1978-01-18 |
SU664562A3 (en) | 1979-05-25 |
LU77684A1 (en) | 1978-01-31 |
AU2650677A (en) | 1979-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1005921A4 (en) | THERAPEUTIC USE OF serotonin 5HT3 RECEPTOR ANTAGONISTS. | |
RU2221563C2 (en) | Pharmaceutical composition for treatment of parkinson's disease and parkinson's syndrome, method for its preparing, method for treatment of parkinson's disease and parkinson's syndrome | |
NL8802059A (en) | ESTERS AND AMIDS OF CYCLIC CARBONIC ACIDS AND CYCLIC ALCOHOLS AND AMINES. | |
IE48370B1 (en) | Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties,pharmaceutical preparations containing same,and intermediates for their preparation | |
CS196290B2 (en) | Process for preparing new compounds | |
HRP20020845A2 (en) | Novel, slow-acting betamimetics, a method for their production and their use as medicaments | |
RU2057120C1 (en) | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamine or pharmaceutically acceptable acid addition salt thereof, process for preparation thereof, pharmaceutical composition having norminephrine absortion inhibitory activity | |
HUT74949A (en) | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists | |
EA004539B1 (en) | Combination therapy for treatment of refractory depression | |
IE63670B1 (en) | Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds | |
EP2887804A1 (en) | Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use | |
JPH01100118A (en) | Novel medicinal composition containing phosphodiesterase inhibitor and thromboxane a2 antagonist, use and manufacture | |
DE19915365A1 (en) | Tetrahydropyridazine derivatives | |
NO772339L (en) | SUBSTITUTED TRIAZOLES. | |
US4032637A (en) | Method of promoting sleep | |
AU673747B2 (en) | Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | |
US4512994A (en) | Long-acting theophylline in medicinal form | |
FR2536072A1 (en) | NEW QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
DE2427207A1 (en) | PROCESS FOR THE PREPARATION OF CONDENSED PYRRENE MERCAPTO COMPOUNDS | |
US4328235A (en) | Suppressing pain with benzothiazol-2(3H)-ones | |
US5652249A (en) | Method of treating depression | |
HU203282B (en) | Process for producing pharmaceutical composition for treating cardiac decomposition containing 7,8-dimethoxy-3-/3-(/2-(3,4-dimethoxy-phenyl)-ethyl/-methyl- -amino)-propyl/-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one | |
US4263300A (en) | Substituted 2-phenylamino-1,3-tetrahydro-2-pyrimidines and salts thereof | |
EP0316668A2 (en) | Use of a tetrahydro-pyrido(2,3-d)pyrimidine for obtaining an analgetic agent | |
NZ243577A (en) | Synergistic anti-hypertensive composition containing tetrahydronaphthalene and pyridodiazepine derivatives |